Morgan Stanley Maintains Overweight on Sempra, Lowers Price Target to $100
Morgan Stanley analyst David Arcaro maintains Sempra (NYSE:SRE) with a Overweight and lowers the price target from $104 to $100.
Share
Why It Matters
A big bank analyst still likes Sempra but lowered their expected price by $4. This means they see the company as good but slightly less valuable than before.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.